Pancreatic ductal adenocarcinoma (PDAC) is one of the few cancers where post-treatment surveillance lacks strong evidence to guide it. Clinics follow general guidelines, but guidelines aren't always followed consistently. These failures are predictable and preventable.
The Recurrence Reality After Resection
For patients who have completed surgery with curative intent, the recurrence risk is steep. A retrospective study on post-resection surveillance with serial imaging and CA 19-9 found that up to 80% of resected pancreatic cancer patients experience recurrence within two years of surgery. Structured, timely follow-up matters most in this narrow window. This is also when clinic workflows are most likely to fail - through delayed imaging, missed CA 19-9 draws, or appointments that slip without being noticed.
The biology of PDAC adds to the operational challenge. The pancreas sits deep in the abdomen, and early recurrence near the surgical bed is hard to tell apart from post-surgery swelling on imaging. Both surveillance timing and quality matter. Whether a scan was ordered is only the first question.
Why Guidelines Leave Clinics With Too Much Room to Vary
NCCN guidelines recommend CT of the chest, abdomen, and pelvis every 3-6 months for the first two years after resection, followed by every 6-12 months thereafter. That is a wide range. ASCO, in its review of surveillance imaging after curative-intent cancer treatment, found that randomized trials haven't established the best imaging frequency for pancreatic cancer. No trial has yet settled which specific interval produces the best outcome for which patient group.
The consequence for clinics is predictable. Without clear evidence, follow-up frequency depends on clinician preference, available slots, and patient adherence. A recent survey across 54 of 57 institutions in the International Pancreatic Cancer Early Detection Consortium (PRECEDE) found that clinics use different surveillance approaches and existing guidelines don't resolve the gaps. Clinics approach questions about which patients need surveillance and how often differently.
Guideline gaps show up on the clinic floor. When a recommendation spans from 3 to 6 months, a busy oncologist often defaults to the longer end. When a patient misses an appointment, the drift widens further. Without an automated alert, no one notices.
Where Clinic Workflows Break Down
The failure modes are operational, not clinical. Three patterns show up in most clinics.
- Appointment drift. A 3-month follow-up slips to 4 months, then 5. Without an automated alert tied to the treatment timeline, no one catches the drift until the patient's next scheduled visit - if the patient arrives at all.
- Fragmented biomarker tracking. CA 19-9, the most frequently ordered tumor marker in post-resection PDAC surveillance, is only useful when its trend is visible. When lab results arrive in a system separate from the imaging record, the clinician must cross-reference manually. A rising CA 19-9 pattern might not trigger an early scan if the clinician can't see all the recent results together.
- Inconsistent imaging interpretation. Research from the Society of Abdominal Radiology's disease focus panel on PDAC found that post-surgery imaging is hard to interpret due to post-surgery swelling in the surgical bed. Without a standardized reporting template, the same finding may be described differently across radiologists, making it hard to spot changes between scans.
These gaps mean recurrence is often found later than it might be. The RADAR-PANC trial was launched because the field lacks clear evidence about post-surgery surveillance for PDAC. Its published trial protocol shows how different clinics' approaches are and how much better a standard approach could work.
What Structured Surveillance Actually Looks Like
Evidence suggests several practices that reduce failures without waiting for RADAR-PANC results.
- Protocol-anchored timelines. Write surveillance intervals into the patient record when therapy ends, not left to the referring team to schedule ad hoc. A fixed protocol creates a baseline that makes it easy to spot when follow-up falls behind.
- Biomarker-triggered imaging escalation. For patients with CA 19-9-producing tumors, a rising level between scans should trigger earlier imaging. You need to see all recent results together, not just the latest number.
- Standardized imaging reports. The Society of Abdominal Radiology has called for standardized reporting templates for PDAC imaging findings. When radiologists and oncologists agree on what to report, it's easier to spot changes between scans.
- Risk-stratified follow-up frequency. Check patients more often if they have higher risk of recurrence, like those with positive lymph nodes at resection. This focuses monitoring where it matters most.
None of these practices require a new trial. They require operational consistency and infrastructure to enforce it.
The Operational Role of Software in Surveillance Adherence
Most surveillance failures in PDAC are workflow problems, not knowledge problems. Clinicians know a CT should be ordered at three months. The failure point is the system that should prompt that order, confirm the result arrived, and flag missing results.
Software that displays a treatment timeline at a glance - rather than burying follow-up schedules inside general appointment calendars - changes what gets done. When a scheduled CT appears as an overdue item on a clinic dashboard, it is harder to overlook. When this week's CA 19-9 value sits beside values from the prior six draws, you can spot a rising trend before it becomes urgent.
This is why oncology software works differently from general scheduling tools. General calendars track appointment slots. Oncology systems track protocols and alert when follow-up falls behind. For a closer look at why that distinction matters across tumor types, see why oncology clinics need treatment timelines, not just calendars.
Lab reports make this worse. When CA 19-9 results arrive as PDF attachments, pulling each value and entering it into a trend view adds time per patient. Across a clinic with dozens of active post-resection PDAC patients, those minutes accumulate, and manual entry introduces risk. Automated lab extraction removes that step entirely. For a closer look at what that workflow change produces in practice, see how AI lab extraction changes clinical routine.
Similar issues affect surveillance for all cancer types, including appointment drift and split data systems. If your clinic is reviewing follow-up protocols beyond PDAC, the same operational analysis applies to other cancers like melanoma.
Closing the Gap Before the Evidence Catches Up
The RADAR-PANC trial may eventually establish clearer evidence for PDAC surveillance intervals. Until then, clinics need consistent systems to stay on track. Protocol-anchored timelines, integrated biomarker tracking, and standardized imaging reports are not new ideas. They are the consistent execution of what oncologists already know should happen, supported by systems that keep teams on track.
A clinic using separate tools for scheduling and lab work will miss drift, trends, and delays, and recurrence will show up late. Consistent surveillance requires the right tools.
Demos take 30 minutes. We will walk you through the surveillance workflow on your clinic's actual patient data. Book a demo to see the treatment timeline and lab intelligence features in context.